The drug Alectinib (Alecensa) received approval by the FDA for the treatment of patients with advanced, metastatic, ALK-positive non-small cell lung cancer.
U.S. regulators approved the drug uridine triacetate (Vistogard) for the treatment of overdoses of the chemotherapy drugs fluorouracil and capecitabine.
Delaying treatment and chemotherapy influences the survival rates of breast cancer patients, two large U.S. studies suggest.
Postmenopausal women with ductal carcinoma in-situ treated with anastrozole saw no difference in outcome compared to treatment with tamoxifen.
Early-stage breast cancer patients who received breast-conserving surgery plus radiation therapy instead of mastectomy lived longer, scientists report.
Cancer patients who shared their symptoms online improved their quality of life and stayed on treatment longer, a new research points out.
Patients with triple-negative breast cancer who had no residual invasive cancer detected after pre-surgery chemotherapy lived longer, scientists discovered.
Premenopausal women whose invasive breast cancers were of the luminal A subtype did not benefit from a treatment with adjuvant chemotherapy.
Breast cancer patients with residual disease after pre-surgery chemotherapy lived longer after being treated with the chemotherapy agent capecitabine.
The combination of the palbociclib with paclitaxel (Taxol) induced positive patient outcomes when administered to estrogen-receptor positive breast cancer patients.
The monoclonal antibody (denosumab) given as adjuvant therapy with aromatase inhibitors reduced disease relapse rate in breast cancer patients.
Counseling before and after a genetic cancer screening helped BRCA 1/2-negative patients make informed decisions and deal with anxiety, a new research reveals.
Breast cancer survivors at risk of developing leukemia due to chemotherapy and/or radiation share certain characteristics, a new analysis shows.
The drug Midostaurin added to standard chemotherapy improved survival in patients with acute myeloid leukemia carrying mutations in the FLT-3 gene, scientists report.
Blinatumomab proved to be efficient and safe for the treatment of adult patients with acute lymphoblastic leukemia.
Multiple myeloma patients treated with daratumumab combined with standard chemotherapy lived longer without disease progression, a new study finds.
Clinical results reveal the effectiveness of ixazomib plus lenalidomide and dexamethasone in treating patients with relapsed and/or refractory multiple myeloma.
Chronic lymphocytic leukemia patients decreased more the risk of death when treated with the cancer drug Imbruvica instead of the chemotherapy chlorambucil.
Warfarin can be used for the long-term treatment of cancer-associated thrombosis, in place of standard treatment low-molecular-weight heparin, a new study suggests.
Relapsed multiple myeloma patients treated with carfilzomib plus dexamethasone instead of bortezomib plus dexamethasone lived twice as long without disease progression.
Scientists reveal that very few low-risk prostate cancer patients followed by watchful waiting are closely monitored as called for in current guidelines.
Complete surgical excision proved to be the best treatment for breast implant-associated anaplastic large-cell lymphoma patients as it led to low recurrence rates.
A new study reveals that depression has a profound impact on five-year survival and recurrence in head and neck cancer patients.
No link was identified between risk of recurrence and antidepressant use in breast cancer patients taking an anti-cancer drug and an antidepressant.
Initial breast surgery was linked to increased and durable survival rates in women with stage IV breast cancer, a new study points out.
Learning how to manage stress early in their breast cancer treatment helped patients live longer without the disease, a randomized trial shows.
The monoclonal antibody, Elotuzumab, received FDA’s approval to be used for the treatment of myeloma in combination with lenalidomide (Revlimid) and dexamethasone.
European regulators have taken a step closer to the treatment of Merkel cell carcinoma, adopting a positive opinion for Orphan Drug designation for avelumab.
The FDA approved the immuno-oncology treatment, Empliciti, for the treatment of patients with multiple myeloma.
Prostate cancer patients playing soccer a few times a week improved muscular strength and bone density, tackling treatment-related side effects.